Physician profile
Joya A Keys
NPI 1982199287
$3,254.09
in general payments reported to CMS, 2019-2025
28 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $150 · 2022: $38.51 · 2023: $678 · 2024: $1,407 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $667.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $364.92 | 2019-2025 | |
| Abbvie INC. | $361.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $255.00 | 2019-2025 | |
| Amgen INC. | $201.66 | 2019-2025 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $173.40 | 2023-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $165.12 | 2019-2020 | |
| Novo Nordisk INC | $152.74 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Sunovion Pharmaceuticals INC. | $123.24 | 2019 | |
| Astellas Pharma US INC | $109.61 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $101.43 | 2023-2025 | Mounjaro, Zepbound |
| Paratek Pharmaceuticals, INC. | $91.22 | 2023-2024 | Nuzyra |
| Insulet Corporation | $76.12 | 2024-2025 | Omnipod |
| Exact Sciences Corporation | $64.16 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $43.59 | 2023-2024 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $39.00 | 2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.67 | 2023-2024 | Caplyta |
| Edwards Lifesciences Corporation | $30.56 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.90 | 2023-2025 | Jardiance, Glyxambi, Tradjenta |
| Lundbeck LLC | $26.73 | 2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $20.37 | 2024 | Abilify Maintena |
| Csl Behring | $20.00 | 2024 | Haegarda |
| Verity Pharmaceuticals INC. | $19.54 | 2024 | Tlando |
| Dexcom, INC. | $18.62 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $15.84 | 2024 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $15.70 | 2025 | Auvelity |
| Kaleo, INC. | $15.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.10 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joya Keys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.